

Strengths

Mitsubishi Tanabe Pharma's strengths backed by its achievements

The MTPC Group's strong drug discovery and drug fostering and evolution capabilities have resulted in the creation of many innovative pharmaceuticals. Underpinning this are the relationships of trust with its stakeholders. We will continue to provide society with new value based on our DNA to challenge and change backed by our more than 300 years of history.

1. Drug discovery capabilities / Drug fostering and evolution capabilities


2. Trust of patients and medical professionals

3. DNA to take on challenges and change

4. Core value chain as a traditional pharmaceutical company

Imusera (Gilenya)

This drug has contributed to the treatment of MS in more than 80 countries and regions as the world's first oral MS treatment agent that is an alternative to injections.



Tenelia, Canaglu (Invokana), Canalia

We have contributed to diabetes treatment with the addition of two medicines created in-house with completely different mechanisms of action and the first combination tablets in Japan.



Radicava (Radicut)

Radicava is the first new drug in nearly 20 years in the U.S. that limits the progress of ALS and helps improve patients' QOL.



Remicade

Remicade is the first antibody in Japan with 13 indications, including rheumatoid arthritis, that contributes to the treatment of a wide range of diseases.





S Strength